Form 4: IGM Biosciences Director, Kathleen Behrens, Reports Stock Transactions

Director Kathleen Behrens reports acquisition of shares via restricted stock units and indirect holdings through trusts.

Summary

• On September 30, 2024, Kathleen Behrens, a director of IGM Biosciences, acquired 3,078 shares of common stock through fully vested restricted stock units (RSUs) at a price of $0.
• These RSUs represent a quarterly retainer paid in common stock according to the company's Outside Director Compensation Policy.
• Following this transaction, Behrens directly owns 16,202 shares.
• Behrens also indirectly owns 330,700 shares through the KBW 2005 Trust, for which she serves as Trustee.
• Additionally, she indirectly owns 29,807 shares and 29,806 shares through Non-Exempt Trusts for Patrick R. Wilsey and Shannon K. Wilsey, respectively, under the Alfred S. Wilsey, Jr. Revocable Trust, where she is also a Trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock transactions by a director. The acquisition of shares through RSUs is a standard compensation practice.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It may influence investor sentiment depending on how the market interprets the director's stock activity.

Key Dates